Dynavax Technologies (NASDAQ:DVAX) Shares Gap Up to $9.10

Share on StockTwits

Dynavax Technologies Co. (NASDAQ:DVAX) shares gapped up before the market opened on Monday . The stock had previously closed at $9.45, but opened at $9.10. Dynavax Technologies shares last traded at $8.73, with a volume of 7,512,411 shares traded.

Several research firms have recently weighed in on DVAX. William Blair reissued a “buy” rating on shares of Dynavax Technologies in a research note on Friday, March 13th. Zacks Investment Research raised Dynavax Technologies from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a research note on Tuesday. Evercore ISI began coverage on Dynavax Technologies in a research note on Monday, June 15th. They set an “outperform” rating and a $14.00 price objective for the company. ValuEngine raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, April 7th. Finally, Cowen reissued a “buy” rating and set a $20.00 price objective on shares of Dynavax Technologies in a research note on Friday, June 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $15.10.

The stock has a fifty day moving average price of $6.07 and a 200-day moving average price of $5.00. The company has a quick ratio of 4.99, a current ratio of 6.63 and a debt-to-equity ratio of 18.31.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). The business had revenue of $10.92 million during the quarter, compared to analysts’ expectations of $10.91 million. Dynavax Technologies had a negative net margin of 310.97% and a negative return on equity of 722.75%. As a group, sell-side analysts expect that Dynavax Technologies Co. will post -0.95 EPS for the current fiscal year.

In related news, SVP Robert Janssen sold 9,000 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $4.43, for a total transaction of $39,870.00. Following the completion of the sale, the senior vice president now directly owns 220,266 shares in the company, valued at $975,778.38. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Andrew A. F. Hack acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were purchased at an average price of $4.84 per share, with a total value of $4,840,000.00. 13.33% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in DVAX. Marshall Wace LLP raised its holdings in shares of Dynavax Technologies by 225.0% during the first quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 11,387 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Dynavax Technologies by 128.6% during the fourth quarter. Principal Financial Group Inc. now owns 22,973 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 12,925 shares in the last quarter. Rhumbline Advisers raised its holdings in Dynavax Technologies by 6.4% during the fourth quarter. Rhumbline Advisers now owns 101,826 shares of the biopharmaceutical company’s stock valued at $582,000 after buying an additional 6,104 shares in the last quarter. Swiss National Bank raised its holdings in Dynavax Technologies by 2.2% during the fourth quarter. Swiss National Bank now owns 160,278 shares of the biopharmaceutical company’s stock valued at $917,000 after buying an additional 3,400 shares in the last quarter. Finally, State Street Corp raised its holdings in Dynavax Technologies by 133.6% during the fourth quarter. State Street Corp now owns 3,442,677 shares of the biopharmaceutical company’s stock valued at $19,692,000 after buying an additional 1,968,652 shares in the last quarter. Institutional investors and hedge funds own 67.05% of the company’s stock.

Dynavax Technologies Company Profile (NASDAQ:DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Recommended Story: Short Selling

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Electronic Arts Inc.  Declines By 11.2%
Short Interest in Electronic Arts Inc. Declines By 11.2%
Wayfair Inc  CTO James R. Miller Sells 328 Shares of Stock
Wayfair Inc CTO James R. Miller Sells 328 Shares of Stock
Altria Group Inc  Shares Sold by Carroll Financial Associates Inc.
Altria Group Inc Shares Sold by Carroll Financial Associates Inc.
Chesley Taft & Associates LLC Lowers Stake in Vanguard Real Estate ETF
Chesley Taft & Associates LLC Lowers Stake in Vanguard Real Estate ETF
IBM Retirement Fund Raises Holdings in Cintas Co.
IBM Retirement Fund Raises Holdings in Cintas Co.
Forte Capital LLC ADV Acquires 4,872 Shares of AT&T Inc.
Forte Capital LLC ADV Acquires 4,872 Shares of AT&T Inc.


 
© 2006-2020 Zolmax.